Cost Effectiveness of Interferon-Gamma Release Assay for Tuberculosis Screening of Rheumatoid Arthritis Patients prior t
- PDF / 136,795 Bytes
- 7 Pages / 612.28 x 790.87 pts Page_size
- 91 Downloads / 212 Views
Mol Diagn Ther 2010; 14 (6): 367-373 1177-1062/10/0006-0367/$49.95/0
ª 2010 Adis Data Information BV. All rights reserved.
Cost Effectiveness of Interferon-Gamma Release Assay for Tuberculosis Screening of Rheumatoid Arthritis Patients prior to Initiation of Tumor Necrosis Factor-a Antagonist Therapy Akiko Kowada Bunkyo City Public Health Center, Bunkyo City, Tokyo, Japan
Abstract
Background: The prevalence of tuberculosis (TB) in rheumatoid arthritis (RA) patients is higher than that in the general population, and RA patients are considered a high-risk group. Currently, TB screening of RA patients receiving immunosuppressive therapy such as tumor necrosis factor-a (TNFa) antagonists is performed by the tuberculin skin test (TST) in Japan. Interferon-gamma release assays (QuantiFERON-TB Gold In-Tube [QFT] and T-SPOT.TB) are new alternatives to the TST to diagnose latent TB infection (LTBI) and active TB, and offer higher specificity and no cross-reactivity with Bacillus Calmette-Gue´rin (BCG) vaccine. We evaluated the cost effectiveness of QFT versus TST in non-BCG-vaccinated and BCGvaccinated RA patients. Methods: We constructed a Markov model to evaluate the cost effectiveness of QFT and TST. The target population is a hypothetical cohort of 1000 RA patients, using a societal perspective and the lifetime horizon. All costs and clinical benefits were discounted at a fixed annual rate of 3%. Results: In base-case analysis, the QFT strategy was the most cost effective ($US1044.52; 23.03499 qualityadjusted life-years [QALYs]) compared with the TST strategy for non-BCG-vaccinated RA patients ($US1824.61; 22.98153 QALYs) and for BCG-vaccinated RA patients ($US2096.34; 22.98153 QALYs) [year 2009 values]. The incidence of TB in RA patients with TNFa antagonist therapy influenced the cost effectiveness. When the incidence of TB in RA patients with TNFa antagonist therapy is under 0.00066, the TST strategy is more cost effective than the QFT strategy. Conclusions: QFT screening is more effective and less costly than the TST for both BCG-vaccinated and nonBCG-vaccinated RA patients prior to TNFa antagonist therapy in Japan. These findings may be applicable to other countries when choosing optimal LTBI screening of RA patients.
Introduction Tumor necrosis factor-a (TNFa) antagonists are increasingly used as an effective treatment in immune-mediated inflammatory diseases such as rheumatoid arthritis (RA). However, RA patients receiving TNFa antagonist have a higher risk of progression from latent tuberculosis infection (LTBI) to active tuberculosis (TB).[1-7] Therefore, it is critical that LTBI and active TB be identified and treated in RA patients prior to initiation of anti-TNFa agents.[8]
Currently, Mycobacterium tuberculosis-specific interferongamma release assays (IGRAs), including QuantiFERON-TB Gold In-Tube (QFT) [Cellestis Limited, Chadstone, VIC, Australia] and T-SPOT.TB (Oxford Immunotec, Oxford, UK), are available as more precise diagnostic methods to screen for both active TB and LTBI, and offer higher s
Data Loading...
